EpilepsyGTx

Canterbury, United Kingdom

EpilepsyGTx is a late-stage biotech company exploring cutting-edge gene therapies to improve the management of focal refractory epilepsy.

$33.0M raised

Dec 2025

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has EpilepsyGTx raised?

EpilepsyGTx has raised $33.0M in total funding. The most recent round was Series A. The last funding was announced in December 2025.

Who are EpilepsyGTx's investors?

EpilepsyGTx's investors include British Business Bank, XGEN Venture, UCL Technology Fund, HTH.

Where is EpilepsyGTx headquartered?

EpilepsyGTx is headquartered in Canterbury, United Kingdom.

What does EpilepsyGTx do?

EpilepsyGTx is a late-stage biotech company exploring cutting-edge gene therapies to improve the management of focal refractory epilepsy.

What stage is EpilepsyGTx at?

EpilepsyGTx is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated December 10, 2025.

MLA

"EpilepsyGTx — Funding & Investors." VCBacked, December 10, 2025, https://www.vcbacked.co/company/epilepsygtx. Accessed July 11, 2026.

APA

VCBacked. (2025). EpilepsyGTx — Funding & Investors. Retrieved July 11, 2026, from https://www.vcbacked.co/company/epilepsygtx

Wikipedia (cite web)

{{cite web |title=EpilepsyGTx — Funding & Investors |url=https://www.vcbacked.co/company/epilepsygtx |website=VCBacked |access-date=July 11, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated December 10, 2025.